-
-
-
-
Description
- Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria.
-
-
Target Organism
-
- No MICs found on DRAMP database
-
Reference
-
- New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.(PMID: 20426497)
-
Medical use
- Osteomyelitis, Bacterial infections (I)
-
Company
- Clinigen Group plc/Innoviva Inc./Pendopharm/Theravance Biopharma Inc./University of Illinois
-
Stage of Development
- In market
-
- Telavancin prevents polymerization of N-acetylmuramic acid (NAM) and N-acetylglucosamine (NAG) and cross-linking of peptidoglycan by binding to D-Ala-D-Ala. As a result, inhibition of bacterial cell wall synthesis occurs. Furthermore, telavancin disrupts membrane potential and cell permeability as a result of the lipophillic side chain moiety. This additional bactericidal mechanism is what sets telavancin apart from vancomycin.
-